{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:57Z","timestamp":1791489717835,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jacc.2015.01.044","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:45:17Z","timestamp":1426088717000},"page":"1385-1394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF\u00a0With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score"],"prefix":"10.1016","volume":"65","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2015.01.044_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2015.01.044_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"Lip","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.01.044_bib3","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2015.01.044_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of\u00a0oral anticoagulation in relation to mortality and\u00a0the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib6","first-page":"781","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2015.01.044_bib8","unstructured":"National Institute for Health and Care Excellence. Atrial Fibrillation: The Management of Atrial Fibrillation. NICE Clinical Guideline 180. 2014. Available at: http:\/\/www.nice.org.uk\/guidance\/cg180\/resources\/guidance-atrial-fibrillation-the-management-of-atrial-fibrillation-pdf. Accessed February 3,\u00a02015."},{"key":"10.1016\/j.jacc.2015.01.044_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib10","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/pace.12445","article-title":"Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA DS -VASc score of 1","volume":"37","author":"Huang","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2015.01.044_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib15","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.01.044_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2015.01.044_bib17","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for\u00a0refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib18","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.01.044_bib19","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2015.01.044_bib20","first-page":"125","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2013.02.001","article-title":"Management of patients with atrial fibrillation (compilation of 2006 ACCF\/AHA\/ESC and 2011 ACCF\/AHA\/HRS recommendations): a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"61","author":"Anderson","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib22","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.01.044_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1160\/TH09-10-0746","article-title":"Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1","volume":"103","author":"Gorin","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib24","first-page":"465","article-title":"Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation","volume":"111","author":"Lahaye","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2015.01.044_bib25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/archinte.164.18.1993","article-title":"Alcohol and risk of atrial fibrillation or flutter: a cohort study","volume":"164","author":"Frost","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2015.01.044_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/CLEP.S59156","article-title":"Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012","volume":"6","author":"Schmidt","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jacc.2015.01.044_bib27","first-page":"381","article-title":"Patient's values and preferences for stroke prevention in atrial fibrillation:\u00a0balancing stroke and bleeding risk with oral\u00a0anticoagulation","volume":"111","author":"Lane","year":"2014","journal-title":"Thromb Haemost"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715004337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715004337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:10:39Z","timestamp":1760015439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109715004337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0735109715004337"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2015.01.044","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725390666.793517219","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF\u00a0With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2015.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}